Regeneron Pharmaceuticals, Inc. REGN

NASDAQ US Health Care Biotechnology

$913.21 ▼ -0.73% ($-6.75)

Index member: S&P 500

Open $915.90

Prev Close $919.96

Day Range $910.02 – $919.72

52W Range $591.52 – $991.73

Market Cap $96.26B

P/E (TTM) 19.42

Beta 0.12

EPS (TTM) $45.28

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-04-02
Shares Out.	103,450,000
Website	regeneron.com/ ↗
Phone	17813705000
Employees	15,410
Revenue	$5.12B
Gross Profit	$4.54B
Net Income	$1.95B
Free Cash Flow	$3.83B
Total Assets	$44.41B
Total Liabilities	$10.91B
Equity	$33.50B

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Regeneron Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol REGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.